期刊
CANCER RESEARCH
卷 81, 期 15, 页码 3956-3957出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-21-0952
关键词
-
类别
The high affinity of an antibody can lead to restricted tumor penetration and heterogeneous distribution, limiting the efficacy of antibody-based therapies. By competitively inhibiting antibody-antigen binding, increased tumor penetration of the antibody and enhanced efficacy of ADCs can be achieved.
The high affinity of an antibody can result in restricted tumor penetration and heterogenous tumor distribution, with preferential binding of the antibody to tumor cells localized around tumor vasculature. This so-called binding site barrier effect limits the efficacy of antibody-based therapies like antibody-drug conjugates (ADC). In this issue, Bordeau and colleagues introduce an original approach to overcome this barrier through transient competitive inhibition of antibody-antigen binding. By coadministration of an anti-idiotypic anti-trastuzumab domain antibody as a competitive inhibitor, increased tumor penetration of trastuzumab as well as enhanced efficacy of the ADC ado-trastuzumab emtansine were observed in tumor-bearing mice
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据